Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026

Key Takeaway: Amylyx Pharmaceuticals is set to present data from the first-in-human, dose-ranging Phase 1 LUMINA trial of AMX0114 in ALS at the upcoming ENCALS 2026 conference. This trial aims to evaluate the safety and efficacy of AMX0114 for patients with Amyotrophic Lateral Sclerosis (ALS). The presentation will provide insights into the trial's findings and implications for future research.